WASHINGTON (AP) — The Food and Drug Administration has named a longtime pharmaceutical executive to run the agency’s drug program, the latest in a string of leadership changes at the agency.

FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all drugs. His appointment comes a month after the center’s acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement.

As the agency’s top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA also is scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause.

Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He also has served as an adjunct professor at Stanford University.

The FDA’s drug center is the agency’s largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs. The drug center hasn’t had a permanent director since January, when Dr. Patrizia Cavazzoni stepped down days before President Donald Trump took office.